J Neuropsychiatry Clin Neurosci 17:421-422, August 2005
doi: 10.1176/appi.neuropsych.17.3.421
© 2005 American Neuropsychiatric Association
Clinical and Research Reports |
Aripiprazole in Psychosis Associated With Parkinson’s Disease
Elmer López-Meza, M.D.,
Angel Ruiz-Chow, M.D. and
Jesus Ramirez-Bermudez, Ph.D.
Received March 3, 2004; revised June 10, 2004; accepted June 15, 2004. From the Departments of Neurology and Neuropsychiatry, National Institute of Neurology and Neurosurgery of México. Address correspondence to Dr. López-Meza, Clinical Investigation Dept., National Institute of Neurology and Neurosurgery of México. Insurgentes sur 3877, Colonia la fama, Tlalpan, Mexico DF 14269; elmerlopez{at}hotmail.com (E-mail).
ABSTRACT
Aripiprazole is an agent for treating schizophrenia. The authors assume that aripiprazole as a dopamine receptor partial agonist may be useful in treating PD patients. Three cases are presented in this study. All patients were evaluated by the same clinician, a neuropsychiatrist well trained in the use of Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI). Aripiprazole was effective for reducing psychosis in each case.
This article has been cited by other articles:
|
|
|
|
 
U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco
Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease
Am. J. Health Syst. Pharm.,
March 1, 2008;
65(5):
414 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Neuropsychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
